Treatment of negative symptoms: Where do we stand, and where do we go?

Schizophrenia Research

Volumn 186, Issue , 2017, Pages 55-62

  Aleman, André ^a   Lincoln, Tania M ^b   Bruggeman, Richard ^a   Melle, Ingrid ^c   Arends, Johan ^d   Arango, Celso ^e   Knegtering, Henderikus ^a,f  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF HAMBURG   (Germany)

^c UNIVERSITY OF OSLO   (Norway)

^d Centre for Intellectual Disability and Mental Health Care GGZ Drenthe   (Netherlands)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f Center for Integrative Psychiatry of Lentis (a Community Mental Health Hospital)   (Netherlands)

Author keywords

Antipsychotics; Cognitive behavioral therapy; Negative symptoms; Schizophrenia; Transcranial magnetic stimulation; Treatment

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; BITOPERTIN; CARBAMAZEPINE; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; FLUOXETINE; GLYCINE; HALOPERIDOL; LAMOTRIGINE; MEMANTINE; MIANSERIN; MINOCYCLINE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; OXYTOCIN; PERPHENAZINE; QUETIAPINE; REBOXETINE; RISPERIDONE; RITANSERIN; SARCOSINE; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

COGNITIVE BEHAVIORAL THERAPY; COGNITIVE REMEDIATION THERAPY; HUMAN; MOTIVATION; NEGATIVE SYNDROME; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SOCIAL COMPETENCE; TRANSCRANIAL DIRECT CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; COGNITIVE THERAPY; COMPLICATION; PROCEDURES; PSYCHOLOGY; PSYCHOSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; HUMANS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TRANSCRANIAL DIRECT CURRENT STIMULATION;

EID: 85006741596     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.05.015     Document Type: Review

References (102)

1. Adams, D.H., Zhang, L., Millen, B.A., Kinon, B.J., Gomez, J.C., Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophr. Res. Treat., 758212, 2014.
2. Aleman, A., Use of repetitive transcranial magnetic stimulation for treatment in psychiatry. Clin. Psychopharmacol. Neurosci. 11:2 (2013), 53–59 (Aug).
3. Aleman, A., Hijman, R., de Haan, E.H., Kahn, R.S., Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 156:9 (1999), 1358–1366 (Sep).
4. Anand, A., Charney, D.S., Oren, D.A., Berman, R.M., Hu, X.S., Cappiello, A., Krystal, J.H., Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57 (2000), 270–276.
5. Arango, C., Kirkpatrick, B., Buchanan, R.W., Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms. J. Nerv. Ment. Dis. 188:1 (2000), 50–53 (Jan).
6. Arango, C., Buchanan, R.W., Kirkpatrick, B., Carpenter, W.T., The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur. Psychiatry 19:1 (2004), 21–26 (Feb).
7. Arango, C., Garibaldi, G., Marder, S.R., Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr. Res. 150:2–3 (2013), 346–352 (Nov).
8. Artaloytia, J.F., Arango, C., Lahti, A., Sanz, J., Pascual, A., Cubero, P., Prieto, D., Palomo, T., Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am. J. Psychiatry 163:3 (2006), 488–493 (Mar).
9. Awad, A.G., Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev. Pharmacoecon. Outcomes Res. 10 (2010), 1–4.
10. Beck, A.T., Rector, N.A., Stolar, N., Grant, P.M., Schizophrenia. Cognitive Theory, Research and Therapy. 2009, Guilford Press, New York.
11. Bellack, A.S., Mueser, K.T., Gingerich, S., Agresta, J., Social skills training for schizophrenia. A Step-by-Step Guide, 1997, Guilford Press, London.
12. Bentall, R.P., Simpson, P.W., Lee, D.A., Williams, S., Elves, S., Brabbins, C., et al. Motivation and avolition in schizophrenia patients: the role of self-efficacy. Psychosis 2 (2010), 12–22.
13. Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J. Clin. Psychiatry 71:3 (2010), 280–286 (Mar).
14. Brunelin, J., Mondino, M., Gassab, L., Haesebaert, F., Gaha, L., Suaud-Chagny, M.F., Saoud, M., Mechri, A., Poulet, E., Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am. J. Psychiatry 169:7 (2012), 719–724 (Jul).
15. Buchanan, R.W., Breier, A., Kirkpatrick, B., Ball, P., Carpenter, W.T. Jr., Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 155:6 (1998), 751–760 (Jun).
16. Buchanan, R.W., Javitt, D.C., Marder, S.R., Schooler, N.R., Gold, J.M., McMahon, R.P., Heresco-Levy, U., Carpenter, W.T., The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 164:10 (2007), 1593–1602.
17. Buchanan, R.W., Panagides, J., Zhao, J., Phiri, P., den Hollander, W., Ha, X., Kouassi, A., Alphs, L., Schooler, N., Szegedi, A., Cazorla, P., Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J. Clin. Psychopharmacol. 32 (2012), 36–45.
18. Buchanan, R.W., Weiner, E., Kelly, D.L., Gold, J.M., Keller, W.R., Waltz, J.A., McMahon, R.P., Gorelick, D.A., Rasagiline in the treatment of the persistent negative symptoms of schizophrenia. Schizophr. Bull. 41:4 (2015), 900–908 (Jul).
19. Bugarski-Kirola, D., Wang, A., Abi-Saab, D., Blättler, T., A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study. Eur. Neuropsychopharmacol. 24:7 (2014), 1024–1036.
20. Cain, C.K., McCue, M., Bello, I., Creedon, T., Tang, D.I., Laska, E., Goff, D.C., D-Cycloserine augmentation of cognitive remediation in schizophrenia. Schizophr. Res., 2014.
21. Calvo, A., Moreno, M., Ruiz-Sancho, A., Rapado-Castro, M., Moreno, C., Sánchez-Gutiérrez, T., Arango, C., Mayoral, M., Intervention for adolescents with early-onset psychosis and their families: a randomized controlled trial. J. Am. Acad. Child Adolesc. Psychiatry 53:6 (2014), 688–696 (Jun).
22. Chung, S.W., Hoy, K.E., Fitzgerald, P.B., Theta-burst stimulation: a new form of TMS treatment for depression?. Depress. Anxiety 32:3 (2015), 182–192 (Mar).
23. Dagani, J., Sisti, D., Abelli, M., Di Paolo, L., Pini, S., Raimondi, S., Rocchi, M.B., Saviotti, F.M., Scocco, P., Totaro, S., Balestrieri, M., de Girolamo, G., Do we need oxytocin to treat schizophrenia? A randomized clinical trial. Schizophr. Res. 172:1–3 (2016), 158–164 (Apr).
24. de la Fuente-Sandoval, C., Reyes-Madrigal, F., Mao, X., León-Ortiz, P., Rodríguez-Mayoral, O., Solís-Vivanco, R., Favila, R., Graff-Guerrero, A., Shungu, D.C., Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy. Int. J. Neuropsychopharmacol., 19(3), 2015 (Sep 12).
25. De Lucena, D., Fernandes, B.S., Berk, M., Dodd, S., Medeiros, D.W., Pedrini, M., Kunz, M., Gomes, F.A., Giglio, L.F., Lobato, M.I., Belmonte-de-Abreu, P.S., Gama, C.S., Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine add-on therapy to clozapine. J. Clin. Psychiatry 70:10 (2009), 1416–1423, 10.4088/JCP.08m04935gry (2009 Oct, Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157).
26. Demirtas-Tatlidede, A., Freitas, C., Cromer, J.R., Safar, L., Ongur, D., Stone, W.S., Seidman, L.J., Schmahmann, J.D., Pascual-Leone, A., Safety and proof of principle study of cerebellar vermal theta burst stimulation in refractory schizophrenia. Schizophr. Res. 124:1–3 (2010), 91–100 (Dec).
27. Deutsch, S.I., Schwartz, B.L., Schooler, N.R., Brown, C.H., Rosse, R.B., Rosse, S.M., Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy. Schizophr. Res. 148:0 (2013), 138–144 (August).
28. Dixon, L., Lehman, A.F., Family interventions for schizophrenia. Schizophr. Bull. 21 (1995), 631–643.
29. Dlabac-de Lange, J.J., Knegtering, R., Aleman, A., Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. J. Clin. Psychiatry 71 (2010), 411–418.
30. Dlabac-de Lange, J.J., Bais, L., van Es, F.D., Visser, B.G., Reinink, E., Bakker, B., van den Heuvel, E.R., Aleman, A., Knegtering, H., Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: results of a multicenter double-blind randomized controlled trial. Psychol. Med. 45:6 (2015), 1263–1275 (Apr).
31. Dollfus, S., Mach, C., Morello, R., Self-evaluation of negative symptoms: a novel tool to assess negative symptoms. Schizophr. Bull. 42 (2016), 571–578.
32. Dominguez Mde, G., Viechtbauer, W., Simons, C.J., van Os, J., Krabbendam, L., Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations. Psychol. Bull. 135:1 (2009), 157–171.
33. Dougall, N., Maayan, N., Soares-Weiser, K., McDermott, L.M., McIntosh, A., Transcranial magnetic stimulation for schizophrenia. Schizophr. Bull. 41 (2015), 1220–1222.
34. Dyck, D.G., Short, R.A., Hendryx, M.S., Norell, D., Myers, M., Patterson, T., et al. Management of negative symptoms among patients with schizophrenia attending multiple-family groups. Psychiatr. Serv. 51 (2000), 513–519.
35. Eak, S.M., Mesholam-Gateley, R.I., Greenwald, D.P., Hogarty, S.S., Keshavan, M.S., Negative symptom improvement during cognitive rehabilitation. Results from a two-year trial of cognitive enhancement therapy. Psychiatry Res. 209 (2013), 21–26.
36. Elis, O., Caponigro, J.M., Kring, A.M., Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin. Psychol. Rev. 33 (2013), 914–928.
37. Evins, A.E., Fitzgerald, S.M., Wine, L., Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am. J. Psychiatry 157 (2000), 826–828 (e.a.).
38. Favrod, J., Giuliani, F., Ernst, F., Bonsack, C., Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia. Perspect. Psychiatr. Care 46 (2010), 171–181.
39. Feifel, D., Shilling, P.D., MacDonald, K., A review of oxytocin's effects on the positive, negative, and cognitive domains of schizophrenia. Biol. Psychiatry 79:3 (2016), 222–233 (Feb 1).
40. Fervaha, G., Takeuchi, H., Lee, J., Foussias, G., Fletcher, P.J., Agid, O., Remington, G., Antipsychotics and amotivation. Neuropsychopharmacology 40:6 (2015), 1539–1548 (May).
41. Fitzgerald, P.B., McQueen, S., Daskalakis, Z.J., Hoy, K.E., A negative pilot study of daily bimodal transcranial direct current stimulation in schizophrenia. Brain Stimul. 7:6 (2014), 813–816 (Nov-Dec).
42. Foussias, G., Siddiqui, I., Fervaha, G., Agid, O., Remington, G., Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. J. Psychopharmacol. 29:2 (2015), 116–126 (Feb).
43. Freitas, C., Fregni, F., Pascual-Leone, A., Meta-analysis of the effects of repetitive transcranial magnetic stimulation (rTMS) on negative and positive symptoms in schizophrenia. Schizophr. Res. 108 (2009), 11–24.
44. Fusar-Poli, P., Papanastasiou, E., Stahl, D., Rocchetti, M., Carpenter, W., Shergill, S., McGuire, P., Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr. Bull. 41:4 (2015), 892–899 (Jul).
45. Giron, M., Fernandez-Yanez, A., Mana-Alvarenga, S., Molina-Habas, A., Nolasco, A., Gomez-Beneyto, M., Efficacy and effectiveness of individual family intervention on social and clinical functioning and family burden in severe schizophrenia: a 2-year randomized controlled study. Psychol. Med. 40 (2010), 73–84.
46. Goff, D.C., Bitopertin: the good news and bad news. JAMA Psychiatry 71 (2014), 621–622.
47. Grant, P.M., Beck, A.T., Asocial beliefs as predictors of asocial behavior in schizophrenia. Psychiatry Res. 177 (2010), 65–70.
48. Grant, P., Huh, G.A., Perivoliotis, D., Stolar, N.M., Beck, A.T., Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch. Gen. Psychiatry 69 (2012), 121–127.
49. Heringa, S.M., Begemann, M.J., Goverde, A.J., Sommer, I.E., Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr. Res., 2015 (doi:S0920-9964(15)00174-7).
50. Hogarty, G.E., Anderson, C.M., Reiss, D.J., et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: I. one-year effects of a controlled study on relapse and expressed emotion. Arch. Gen. Psychiatry 43 (1986), 633–642.
51. Jiawan, V.C., Arends, J., Slooff, C.J., Knegtering, H., Pharmacological treatment of negative symptoms in schizophrenia; research and practice. [Medicamenteuze interventie bij negatieve symptomen bij patienten met schizofrenie]. Tijdschr. Psychiatrie 52:9 (2010), 627–637.
52. John, J.P., Lukose, A., Manjunath, S., Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study. Pharmacopsychiatry 47:6 (2014), 202–209.
53. Kay, S.R., Fiszbein, A., Opler, L.A., The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:2 (1987), 261–276.
54. Kegeles, L.S., Mao, X., Stanford, A.D., Girgis, R., Ojeil, N., Xu, X., Gil, R., Slifstein, M., Abi-Dargham, A., Lisanby, S.H., Shungu, D.C., Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 69:5 (2012), 449–459 (May).
55. Kelly, D.L., Vyas, G., Richardson, C.M., Koola, M., McMahon, R.P., Buchanan, R.W., Wehring, H.J., Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res. 133:1–3 (2011), 257–258 (Dec).
56. Kelly, D.L., Sullivan, K.M., McEvoy, J.P., McMahon, R.P., Wehring, H.J., Gold, J.M., Liu, F., Warfel, D., Vyas, G., Richardson, C.M., Fischer, B.A., Keller, W.R., Koola, M.M., Feldman, S.M., Russ, J.C., Keefe, R.S., Osing, J., Hubzin, L., August, S., Walker, T.M., Buchanan, R.W., Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J. Clin. Psychopharmacol. 35:4 (2015), 374–381 (Aug).
57. Kinon, B.J., Zhang, L., Millen, B.A., Osuntokun, O.O., Williams, J.E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., Jarkova, N., HBBI Study Group, A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol. 31:3 (2011), 349–355 (Jun).
58. Kinon, B.J., Millen, B.A., Zhang, L., McKinzie, D.L., Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol. Psychiatry, 2015, 10.1016/j.biopsych.2015.03.016 (Mar 19. pii:S0006-3223(15)00254-1).
59. Kirkpatrick, B., Fenton, W.S., Carpenter, W.T., Marder, S.R., The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 32 (2006), 214–219.
60. Kirschner, M., Aleman, A., Kaiser, S., Secondary negative symptoms – a review of mechanisms, assessment and treatment. Schizophr. Res. 186 (2017), 29–38.
61. Klingberg, S., Wölwer, W., Engel, C., Wittorf, A., Herrlich, J., Meisner, C., et al. Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr. Bull. 37 (2011), S98–S110.
62. Kring, A.M., Gur, R.E., Blanchard, J.J., Horan, W.P., Reise, S.P., The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am. J. Psychiatry 170:2 (2013), 165–172 (Feb).
63. Krystal, J.H., Anticevic, A., Toward illness phase-specific pharmacotherapy for schizophrenia. Biol. Psychiatry 78:11 (2015), 738–740 (Dec 1).
64. Lane, H.Y., Chang, Y.C., Liu, Y.C., Chiu, C.C., Tsai, G.E., Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry 62:11 (2005), 1196–1204 (Nov).
65. Lecrubier, Y., Quintin, P., Bouhassira, M., Perrin, E., Lancrenon, S., The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr. Scand. 114:5 (2006), 319–327 (Nov).
66. Leucht, S., Corves, C., Arbter, D., Engel, R.R., Li, C., Davis, J.M., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:9657 (2009), 31–41 (Jan 3).
67. Li, Z., Yin, M., Lyu, X.L., Zhang, L.L., Du, X.D., Hung, G.C., Delayed effect of repetitive transcranial magnetic stimulation (rTMS) on negative symptoms of schizophrenia: findings from a randomized controlled trial. Psychiatry Res. 240 (2016), 333–335 (Apr 22).
68. Liemburg, E., Castelein, S., Stewart, R., van der Gaag, M., Aleman, A., Knegtering, H., et al. Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. J. Psychiatr. Res. 47 (2013), 718–725.
69. Lincoln, T.M., Mehl, S., Kesting, M.-L., Rief, W., Negative symptoms and social cognition. Detecting suitable targets for psychological interventions. Schizophr. Bull. 37 (2011), S23–S32.
70. Lindenmayer, J.P., Nasrallah, H., Pucci, M., James, S., Citrome, L., A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr. Res. 147:2–3 (2013), 241–252.
71. Liu, F., Guo, X., Wu, R., Ou, J., Zheng, Y., Zhang, B., Zhao, J., Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial. Schizophr. Res. 153:1–3 (2014), 169–176.
72. Lysaker, P.H., Davis, L.W., Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition. Health Qual. Life Outcomes, 2, 2004, 15 (z'Ω`, Mar;153(1-3):177-83).
73. Möller, H.J., Czobor, P., Pharmacological treatment of negative symptoms in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 265:7 (2015), 567–578 (Oct).
74. Möller, H.J., Müller, H., Borison, R.L., Schooler, N.R., Chouinard, G., A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 245:1 (1995), 45–49.
75. Mucci, A., Merlotti, E., Üçok, A., Aleman, A., Galderisi, S., Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr. Res. 186 (2017), 19–28.
76. NICE, Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE clinical guideline 82. Available at www.nice.org.uk/CG82, 2009.
77. Oya, K., Kishi, T., Iwata, N., Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta- analysis of randomized controlled trials. Hum. Psychopharmacol. 29:5 (2014), 483–491 (Sep).
78. Paraschakis, A., Tackling negative symptoms of schizophrenia with memantine. Case Reports in Psychiatry, 2014, 2014, 384783.
79. Patel, R., Jayatilleke, N., Broadbent, M., Chang, C.K., Foskett, N., Gorrell, G., Hayes, R.D., Jackson, R., Johnston, C., Shetty, H., Roberts, A., McGuire, P., Stewart, R., Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. BMJ Open, 5(9), 2015, e007619 (Sep 7).
80. Paulus, W., Transcranial electrical stimulation (tES - tDCS; tRNS, tACS) methods. Neuropsychol. Rehabil. 21:5 (2011), 602–617 (Oct).
81. Priori, A., Hallett, M., Rothwell, J.C., Repetitive transcranial magnetic stimulation or transcranial direct current stimulation?. Brain Stimul. 2:4 (2009), 241–245 (Oct).
82. Radua, J., Schmidt, A., Borgwardt, S., Heinz, A., Schlagenhauf, F., McGuire, P., Fusar-Poli, P., Ventral striatal activation during reward processing in psychosis: a neurofunctional meta-analysis. JAMA Psychiatry 72:12 (2015), 1243–1251 (Dec).
83. Roder, V., Mueller, D., Mueser, K.T., Brenner, H.D., Integrated psychological therapy (IPT) for schizophrenia: is it effective?. Schizophr. Bull. 32 (2006), 81–93.
84. Shi, C., Yu, X., Cheung, E.F., Shum, D.H., Chan, R.C., Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Res. 215 (2014), 505–513.
85. Singh, S.P., Singh, V., Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 25:10 (2011), 859–885 (Oct 1).
86. Singh, S.P., Singh, V., Kar, N., Chan, K., Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br. J. Psychiatry 197:3 (2010), 174–179.
87. Smith, R.C., Boules, S., Mattiuz, S., Youssef, M., Tobe, R.H., Sershen, H., Lajtha, A., Nolan, K., Amiaz, R., Davis, J.M., Effects of transcranial direct current stimulation (tDCS) on cognition, symptoms, and smoking in schizophrenia: a randomized controlled study. Schizophr. Res., 16, 2015 (Jul).
88. Staring, A.B., Ter Huurne, M.A., van der Gaag, M., Cognitive Behavioral Therapy for negative symptoms (CBT-n) in psychotic disorders: a pilot study. J. Behav. Ther. Exp. Psychiatry 44 (2013), 300–306.
89. Stauffer, V.L., Millen, B.A., Andersen, S., Kinon, B.J., Lagrandeur, L., Lindenmayer, J.P., Gomez, J.C., Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr. Res. 150:2–3 (2013), 434–441 (Nov).
90. Teng, B.L., Nonneman, R.J., Agster, K.L., Nikolova, V.D., Davis, T.T., Riddick, N.V., Baker, L.K., Pedersen, C.A., Jarstfer, M.B., Moy, S.S., Prosocial effects of oxytocin in two mouse models of autism spectrum disorders. Neuropharmacology 72 (2013), 187–196.
91. Terevnikov, V., Joffe, G., Stenberg, J.H., Randomized controlled trials of add-on antidepressants in schizophrenia. Int. J. Neuropsychopharmacol., 2015 (doi:pyv049 [pii]).
92. Tiihonen, J., Wahlbeck, K., Kiviniemi, V., The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 109 (2009), 10–14.
93. Tuominen, H.J., Tiihonen, J., Wahlbeck, K., Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr. Res. 72:2–3 (2005), 225–234.
94. Turner, D.T., van der Gaag, M., Karyotaki, E., Cuijpers, P., Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am. J. Psychiatr. 171 (2014), 523–538.
95. Veerman, S.R., Schulte, P.F., Begemann, M.J., Engelsbel, F., de Haan, L., Clozapine augmented with glutamate modulators in refractory schizophrenia: a review and metaanalysis. Pharmacopsychiatry 47:6 (2014), 185–194.
96. Veerman, S.R., Schulte, P.F., Smidt, J.D., de Haan, L., Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol. Med. 6 (2016), 1–13 (Apr). (2014, [Epub ahead of print]).
97. Velligan, D., Roberts, D., Mintz, J., Maples, N., Li, X., Medellin, E., et al. A randomized pilot study of MOtiVation and Enhancement (MOVE) Training for negative symptoms in schizophrenia. Schizophr. Res. 165 (2015), 175–180.
98. Velthorst, E., Koeter, M., van der Gaag, M., et al. Adapted cognitive–behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. Psychol. Med. 45 (2015), 453–465.
99. Vidal, C., Reese, C., Fischer, B.A., Chiapelli, J., Himelhoch, S., Meta-analysis of efficacy of mirtazapine as an adjunctive treatment of negative symptoms in schizophrenia. Clin. Schizophr. Relat. Psychoses, 2013, 1–24 (doi:H63X60J285V6X45K).
100. Walling, D., Marder, S.R., Kane, J., Fleischhacker, W.W., Keefe, R.S., Hosford, D.A., Dvergsten, C., Segreti, A.C., Beaver, J.S., Toler, S.M., Jett, J.E., Dunbar, G.C., Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. Schizophr. Bull. 42:2 (2016), 335–343.
101. Wobrock, T., Guse, B., Cordes, J., Wölwer, W., Winterer, G., Gaebel, W., et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol. Psychiatry 77:11 (2015), 979–988 (Jun 1).
102. Wykes, T., Steel, C., Everitt, B., Tarrier, N., Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr. Bull. 34 (2008), 523–537.